NICE - Endorsed Technology Appraisals 2019/2020

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2019/2020

The following technology appraisals have been endorsed during 2019/20. Information on technology appraisals endorsed in previous years can be found on the homepage. 

Fully Endorsed 

March 2020

NICE TA 622 - Sotagliflozin with insulin for treating type 1 diabetes

NICE TA 623 - Patiromer for treating hyperkalaemia

NICE TA 624 - Peginterferon beta-1a for treating relapsing - remitting multiple sclerosis

February 2020

NICE TA 617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

NICE TA 619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

NICE TA 620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

  • This guidance updates and replaces NICE Technology Appraisal TA381, which was endorsed by the DoH in February 2016.

NICE TA 621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

January 2020

NICE TA 614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome

NICE TA 615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome

NICE TA 616 - Cladribine for treating relapsing–remitting multiple sclerosis (review of TA493)

  • This guidance updates and replaces NICE Technology Appraisal TA493, which was endorsed by the DoH in December 2017.

December 2019

NICE TA 612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

NICE TA 613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (part review of TA301)

  • This guidance partially updates NICE Technology Appraisal TA301, which was endorsed by the DoH in December 2013.

November 2019

NICE TA 605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea

NICE TA 606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema

NICE TA 607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease

NICE TA 610 - Pentosan polysulfate sodium for treating bladder pain syndrome

NICE TA 611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

October 2019

NICE TA 599 - Sodium zirconium cyclosilicate for treating hyperkalaemia

NICE TA 600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer

NICE TA 604 - Idelalisib for treating refractory follicular lymphoma

September 2019

NICE TA 592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma

NICE TA 593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

NICE TA 595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis 

NICE TA 597 - Dapagliflozin with insulin for treating type 1 diabetes

NICE TA 598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

August 2019

NICE TA 588 - Nusinersen for treating spinal muscular atrophy

NICE TA 589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

NICE TA 590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

NICE TA 591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant

July 2019

NICE TA 583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

NICE TA 584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer

NICE TA 585 - Ocrelizumab for treating primary progressive multiple sclerosis

NICE TA 586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (partial review of TA171) 

  • For third- or further-line use, please see NICE Technology Appraisal TA171 -  Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies, endorsed by DoH in September 2010. 

NICE TA 587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma

June 2019

NICE TA 579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy

NICE TA 580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer

NICE TA 581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

May 2019

NICE TA 573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple

NICE TA 574 - Certolizumab pegol for treating moderate to severe plaque psoriasis

NICE TA 575 - Tildrakizumab for treating moderate to severe plaque psoriasis

NICE TA 577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

NICE TA 578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

NICE TA 566 - Cochlear implants for children and adults with severe to profound deafness (part review of TA166)

  • This guidance updates and replaces NICE Technology Appraisal TA166, which was endorsed by the DoH in November 2011.

April 2019

NICE TA 565 - Benralizumab for treating severe eosinophilic asthma

NICE TA 567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

NICE TA 569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer

NICE TA 571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib

NICE TA 572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes

NICE TA 559 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies

Back to top